Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.37 |
| ▸ | TNK2 | Q07912 | 4/20 | 0.36 |
| ▸ | CDK4 | P11802 | 8/20 | 0.36 |
| ▸ | CCND1 | P24385 | 6/20 | 0.36 |
| ▸ | WEE1 | P30291 | 2/20 | 0.36 |
| ▸ | AURKA | O14965 | 2/20 | 0.35 |
| ▸ | CDK1 | P06493 | 2/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.35 |
| ▸ | CDK7 | P50613 | 2/20 | 0.35 |
| ▸ | INSR | P06213 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.35 |
| ▸ | FLT1 | P17948 | 1/20 | 0.35 |
| ▸ | FLT4 | P35916 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15035011 | 0.79 | PTK2 (0.41) | WEE1JAK2BRD4JAK3 | |
| SCHEMBL15034782 | 0.78 | WEE1 (0.41) | WEE1JAK2BRD4JAK3 | |
| SCHEMBL15034976 | 0.77 | MAPK14 (0.40) | EGFRTNK2WEE1FGFR1JAK3 | |
| SCHEMBL15034800 | 0.76 | TNK2 (0.39) | EGFRTNK2WEE1FGFR1JAK3 | |
| SCHEMBL15041239 | 0.76 | TNK2 (0.38) | EGFRTNK2WEE1JAK3 | |
| SCHEMBL15041343 | 0.76 | TNK2 (0.38) | EGFRTNK2WEE1FGFR1JAK3 | |
| SCHEMBL15277167 | 0.75 | TNK2 (0.39) | EGFRTNK2SRCFGFR1JAK3 | |
| SCHEMBL15035038 | 0.75 | JAK3 (0.39) | CDK4CCND1WEE1FGFR1JAK2 | |
| SCHEMBL15035669 | 0.75 | FGFR1 (0.36) | EGFRTNK2CDK4CCND1WEE1 | |
| SCHEMBL15035797 | 0.75 | TNK2 (0.38) | EGFRTNK2CDK4CCND1FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130231348-A1 | 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130231348-A1 | 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231348-A1 | 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | PAK2, PAK3, PAK5 | EGFR 2355/4885TNK2 10/4885CDK4 408/4885 |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | EGFR 737/4885TNK2 7/4885CDK4 404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.